Protocol Ledger

NCT06647862 · Phase III · RECRUITING

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Interventional Phase III clinical trial protocol NCT06647862 sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-11 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06647862
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06647862
Protocol FieldVerified Registry Value
NCT IdentifierNCT06647862
Consolidated Lead SponsorImmuneOnco Biopharmaceuticals (Shanghai)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2024-11-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI